Skip to main content
. 2024 Dec 19;12:159. doi: 10.1186/s40364-024-00705-7

Table 1.

LILRB specific monoclonal antibodies in clinical trial for use in hematologic malignancies

Therapeutic Agent Target Disease Trial Phase Trial number
IO-202 LILRB4 r/r AML, r/r CMML Phase 1, recruiting NCT04372433
MK-0482 LILRB4 r/r myelomonocytic or monoblastic/monocytic AML, r/r CMML Phase 1b, terminated NCT05038800